240 related articles for article (PubMed ID: 31131397)
1. Avoiding over- and undertreatment in patients with resected node-positive breast cancer with the use of gene expression signatures: are we there yet?
Matikas A; Foukakis T; Swain S; Bergh J
Ann Oncol; 2019 Jul; 30(7):1044-1050. PubMed ID: 31131397
[TBL] [Abstract][Full Text] [Related]
2. Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: a systematic review and economic analysis.
Harnan S; Tappenden P; Cooper K; Stevens J; Bessey A; Rafia R; Ward S; Wong R; Stein RC; Brown J
Health Technol Assess; 2019 Jun; 23(30):1-328. PubMed ID: 31264581
[TBL] [Abstract][Full Text] [Related]
3. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(23):1-57. PubMed ID: 23074401
[TBL] [Abstract][Full Text] [Related]
4. A cost-consequence model of using the 21-gene assay to identify patients with early-stage node-positive breast cancer who benefit from adjuvant chemotherapy in the Netherlands.
Simons MJHG; Machielsen PM; Spoorendonk JA; Ignacio T; Drost PB; Jacobs T; de Jongh FE
J Med Econ; 2024; 27(1):445-454. PubMed ID: 38436289
[TBL] [Abstract][Full Text] [Related]
5. Recommendations from the EGAPP Working Group: does the use of Oncotype DX tumor gene expression profiling to guide treatment decisions improve outcomes in patients with breast cancer?
Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group*
Genet Med; 2016 Aug; 18(8):770-9. PubMed ID: 26681310
[TBL] [Abstract][Full Text] [Related]
6. Gene Expression Profiling Tests for Early-Stage Invasive Breast Cancer: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2020; 20(10):1-234. PubMed ID: 32284770
[TBL] [Abstract][Full Text] [Related]
7. Clinical Utility of Multigene Profiling Assays in Early-Stage Invasive Breast Cancer: An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline.
Blanchette P; Sivajohanathan D; Bartlett J; Eisen A; Feilotter H; Pezo R; Turashvili G; Williams P
Curr Oncol; 2022 Apr; 29(4):2599-2615. PubMed ID: 35448187
[TBL] [Abstract][Full Text] [Related]
8. Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: Update of the ASCO Endorsement of the Cancer Care Ontario Guideline.
Henry NL; Somerfield MR; Abramson VG; Ismaila N; Allison KH; Anders CK; Chingos DT; Eisen A; Ferrari BL; Openshaw TH; Spears PA; Vikas P; Stearns V
J Clin Oncol; 2019 Aug; 37(22):1965-1977. PubMed ID: 31206315
[TBL] [Abstract][Full Text] [Related]
9. Gene expression signatures in older patients with breast cancer: A systematic review.
Lemij AA; Baltussen JC; de Glas NA; Kroep JR; Derks MGM; Liefers GJ; Portielje JEA
Crit Rev Oncol Hematol; 2023 Jan; 181():103884. PubMed ID: 36442749
[TBL] [Abstract][Full Text] [Related]
10. Impact of Oncotype DX breast Recurrence Score testing on adjuvant chemotherapy use in early breast cancer: Real world experience in Greater Manchester, UK.
Loncaster J; Armstrong A; Howell S; Wilson G; Welch R; Chittalia A; Valentine WJ; Bundred NJ
Eur J Surg Oncol; 2017 May; 43(5):931-937. PubMed ID: 28111076
[TBL] [Abstract][Full Text] [Related]
11. The impact of a genomic assay (Oncotype DX) on adjuvant treatment recommendations in early breast cancer.
de Boer RH; Baker C; Speakman D; Chao CY; Yoshizawa C; Mann GB
Med J Aust; 2013 Aug; 199(3):205-8. PubMed ID: 23909545
[TBL] [Abstract][Full Text] [Related]
12. Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays.
Albain KS; Paik S; van't Veer L
Breast; 2009 Oct; 18 Suppl 3():S141-5. PubMed ID: 19914534
[TBL] [Abstract][Full Text] [Related]
13. The effects of lymph node status on predicting outcome in ER+ /HER2- tamoxifen treated breast cancer patients using gene signatures.
Cockburn JG; Hallett RM; Gillgrass AE; Dias KN; Whelan T; Levine MN; Hassell JA; Bane A
BMC Cancer; 2016 Jul; 16():555. PubMed ID: 27469239
[TBL] [Abstract][Full Text] [Related]
14. Impact of Genomic Assay Testing and Clinical Factors on Chemotherapy Use After Implementation of Standardized Testing Criteria.
Natsuhara KH; Losk K; King TA; Lin NU; Camuso K; Golshan M; Pochebit S; Brock JE; Bunnell CA; Freedman RA
Oncologist; 2019 May; 24(5):595-602. PubMed ID: 30076279
[TBL] [Abstract][Full Text] [Related]
15. Prognostic and predictive indicators in early-stage breast cancer and the role of genomic profiling: Focus on the Oncotype DX
Curtit E; Mansi L; Maisonnette-Escot Y; Sautière JL; Pivot X
Eur J Surg Oncol; 2017 May; 43(5):921-930. PubMed ID: 28087099
[TBL] [Abstract][Full Text] [Related]
16. Budget impact of the Oncotype DX® test compared to other gene expression tests in patients with early breast cancer in Germany.
Lux MP; Minartz C; Müller-Huesmann H; Sandor MF; Herrmann KH; Radeck-Knorre S; Neubauer AS
Cancer Treat Res Commun; 2022; 31():100519. PubMed ID: 35093682
[TBL] [Abstract][Full Text] [Related]
17. The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial).
Penault-Llorca F; Filleron T; Asselain B; Baehner FL; Fumoleau P; Lacroix-Triki M; Anderson JM; Yoshizawa C; Cherbavaz DB; Shak S; Roca L; Sagan C; Lemonnier J; Martin AL; Roché H
BMC Cancer; 2018 May; 18(1):526. PubMed ID: 29728098
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant chemotherapy and survival outcome in node-negative breast cancer with a 21-gene recurrence score of 26-30.
Yang SP; Yao J; Zhou P; Lian CL; Wang J; Fang MX; Wu SG
Future Oncol; 2021 Jun; 17(17):2183-2192. PubMed ID: 33605163
[TBL] [Abstract][Full Text] [Related]
19. Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update.
Andre F; Ismaila N; Allison KH; Barlow WE; Collyar DE; Damodaran S; Henry NL; Jhaveri K; Kalinsky K; Kuderer NM; Litvak A; Mayer EL; Pusztai L; Raab R; Wolff AC; Stearns V
J Clin Oncol; 2022 Jun; 40(16):1816-1837. PubMed ID: 35439025
[TBL] [Abstract][Full Text] [Related]
20. Impact of the 21-gene recurrence score assay compared with standard clinicopathologic guidelines in adjuvant therapy selection for node-negative, estrogen receptor-positive breast cancer.
Partin JF; Mamounas EP
Ann Surg Oncol; 2011 Nov; 18(12):3399-406. PubMed ID: 21537874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
